Efficacy and Tolerability of Curmune Formulation in the Management of COVID-19: A Randomised Comparative Clinical Study.

Background: COVID-19 outbreak is a global threat, with lack of vaccines and antiviral medicine exaggerating the issue further. The Centers for Disease Control and Prevention recommend maintenance of personal hygiene as a modality to reduce chances of infection. Yet, another way is by improving the immunity. Viral infections are depended on body’s natural defences. Authors of current paper have studied the formulation containing proprietary blend of natural ingredients viz. Curcumin, Vitamin C, and Zinc based on their individual reported activities against SARS-CoV-2’s peptide. Objective: To evaluate role of Curmune Tablets in the management of SARS-CoV-2 Infection (COVID-19) and its tolerability in comparison with standard treatment protocol designed by Ministry of Health and Family Welfare (MOHFW). Study design: In a randomized study, 100 patients tested positive for COVID-19 were enrolled during the month of September to December 2020 from Vakratund Hospital, Nashik, Maharashtra, India. The enrolled patients were administered either Curmune Tablets twice daily or given standard treatment protocol designed by MOHFW for 10 days. The patients were evaluated for decrease in axillary temperature; SpO2 and VAS score for cough and respiratory distress along with evaluating markers such as Interleukin-6, D-dimer, Ferritin and C Reactive Protein. Results: In the Curmune group, within two to three days, temperature reduced considerably to afebrile level in all the subjects and remained afebrile till end of study. While in the standard treatment group, temperature reduced to afebrile stage in all the subjects by 4 days and thereafter remained afebrile till the end of study. The elevated levels of serum Interleukin-6, Didimer, Ferritin and C-Reactive Protein at baseline dropped considerably within normal limits within 10 days in the Curmune group in comparison to standard treatment group. Conclusion: Curmune has shown for the first time to be useful in management of COVID-19 positive patients along with improvement in the immunity, within 48 to 36 hours of starting treatment. Curmune Tablets were well tolerated without any side effects in any of the patients treated, throughout the study duration. [ABSTRACT FROM AUTHOR]